Skip to main content
Advertisement

Main menu

  • Home
  • Content
    • Current Issue
    • Accepted Manuscripts
    • Article Preview
    • Past Issue Archive
    • Video Articles
    • AJNR Case Collection
    • Case of the Week Archive
    • Case of the Month Archive
    • Classic Case Archive
  • Special Collections
    • AJNR Awards
    • Low-Field MRI
    • Alzheimer Disease
    • ASNR Foundation Special Collection
    • Photon-Counting CT
    • View All
  • Multimedia
    • AJNR Podcasts
    • AJNR SCANtastic
    • Trainee Corner
    • MRI Safety Corner
    • Imaging Protocols
  • For Authors
    • Submit a Manuscript
    • Submit a Video Article
    • Submit an eLetter to the Editor/Response
    • Manuscript Submission Guidelines
    • Statistical Tips
    • Fast Publishing of Accepted Manuscripts
    • Graphical Abstract Preparation
    • Imaging Protocol Submission
    • Author Policies
  • About Us
    • About AJNR
    • Editorial Board
    • Editorial Board Alumni
  • More
    • Become a Reviewer/Academy of Reviewers
    • Subscribers
    • Permissions
    • Alerts
    • Feedback
    • Advertisers
    • ASNR Home

User menu

  • Alerts
  • Log in

Search

  • Advanced search
American Journal of Neuroradiology
American Journal of Neuroradiology

American Journal of Neuroradiology

ASHNR American Society of Functional Neuroradiology ASHNR American Society of Pediatric Neuroradiology ASSR
  • Alerts
  • Log in

Advanced Search

  • Home
  • Content
    • Current Issue
    • Accepted Manuscripts
    • Article Preview
    • Past Issue Archive
    • Video Articles
    • AJNR Case Collection
    • Case of the Week Archive
    • Case of the Month Archive
    • Classic Case Archive
  • Special Collections
    • AJNR Awards
    • Low-Field MRI
    • Alzheimer Disease
    • ASNR Foundation Special Collection
    • Photon-Counting CT
    • View All
  • Multimedia
    • AJNR Podcasts
    • AJNR SCANtastic
    • Trainee Corner
    • MRI Safety Corner
    • Imaging Protocols
  • For Authors
    • Submit a Manuscript
    • Submit a Video Article
    • Submit an eLetter to the Editor/Response
    • Manuscript Submission Guidelines
    • Statistical Tips
    • Fast Publishing of Accepted Manuscripts
    • Graphical Abstract Preparation
    • Imaging Protocol Submission
    • Author Policies
  • About Us
    • About AJNR
    • Editorial Board
    • Editorial Board Alumni
  • More
    • Become a Reviewer/Academy of Reviewers
    • Subscribers
    • Permissions
    • Alerts
    • Feedback
    • Advertisers
    • ASNR Home
  • Follow AJNR on Twitter
  • Visit AJNR on Facebook
  • Follow AJNR on Instagram
  • Join AJNR on LinkedIn
  • RSS Feeds

AJNR Awards, New Junior Editors, and more. Read the latest AJNR updates

Research ArticleNeurointervention
Open Access

Stenting versus Medical Treatment for Severe Symptomatic Intracranial Stenosis

C.-W. Tang, F.-C. Chang, C.-M. Chern, Y.-C. Lee, H.-H. Hu and I.-H. Lee
American Journal of Neuroradiology May 2011, 32 (5) 911-916; DOI: https://doi.org/10.3174/ajnr.A2409
C.-W. Tang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
F.-C. Chang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C.-M. Chern
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Y.-C. Lee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H.-H. Hu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
I.-H. Lee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • Responses
  • References
  • PDF
Loading

Abstract

BACKGROUND AND PURPOSE: Intracranial atherosclerosis is especially prevalent in Asians, but intracranial stent placement and medical treatment for severe intracranial stenosis are controversial. Thus, we compared long-term outcomes of these 2 therapeutic approaches in an Asian population.

MATERIALS AND METHODS: Patients with angiographically proved severe (≥70%) symptomatic intracranial atherosclerosis, with or without stent placement, were retrospectively reviewed at a single center between 2002 and 2009, with adjustments for age, sex, vascular risk factors, degree of baseline stenosis, and baseline functional status.

RESULTS: Of the 114 patients followed from 3 to 36 months (mean, 17.3 months) after initial diagnosis, 53 received 56 stents in addition to medical treatment (stent-placement group), and 61 matched patients received only medical treatment (medical group). Total clinical events, including stroke, TIA, and vascular death, were 12 (22.6%) and 15 (24.6%) in the stent-placement and medical groups, respectively (P = .99). The stent-placement group had significantly better functional outcomes than the medical group (94.3% versus 78.7% for mRS scores of 0–3, P = .045). Most events in the stent-placement group occurred within the first week of the periprocedural period (17.0%) as minor embolic or perforator infarctions, and the rate of events decreased thereafter (5.7%, P = .07). Stent placement over the perforator-rich MCA and BA independently predicted periprocedural events on multivariate regression analysis. In the medical group, events increased in frequency (21.7%) and severity with time.

CONCLUSIONS: Although the total ischemic event rate was similar in the 2 groups during a 3-year follow-up, the stent-placement group had a more favorable functional outcome despite minor periprocedural strokes.

Abbreviations

ACA
anterior cerebral artery
ADC
apparent diffusion coefficient
B
balloon-mounted stent
BA
basilar artery
BP
blood pressure
CS
carotid siphon
CVA
cerebrovascular accident
DSA
digital subtraction angiography
DWI
diffusion-weighted imaging
HbA1c
glycated hemoglobin
ICA
internal carotid artery
ICH
intracerebral hemorrhage
MCA
middle cerebral artery
mRS
modified Rankin Scale
NIH
National Institutes of Health
NS
not significant
SAH
subarachnoid hemorrhage
TIA
transient ischemic attack
VA
vertebral artery
VBJ
vertebrobasilar junction
WASID
Warfarin-Aspirin Symptomatic Intracranial Disease

Intracranial arterial stenosis accounts for 33%–54% of ischemic strokes in Asian populations.1 The risk of ischemic stroke from a symptomatic stenotic intracranial artery is high despite medical treatment.2 According to the prospective WASID study, the 1-year risk of ischemic stroke in the territory of a symptomatic stenotic (≥50%) intracranial artery was approximately 11%–12%, despite high-dose aspirin or warfarin therapy. With a degree of stenosis >70%, the ipsilateral stroke rate at 1 year increased to 18%–23%.3,4

With the emergence of intracranial angioplasty and stent placement, the disease course and therapeutic trends have changed.5,6 In a review of 1177 procedures of intracranial stent placement from 31 studies, the technical success rate was >90%; however, widely variable periprocedural complications (4.4%–50%) were observed.7,8 A higher degree of stenosis (≥70%) was not correlated with more of these complications.4,9–11 Using the NIH Wingspan Multicenter Stent-Placement Registry, a comparison between 158 patients receiving stents and 254 matched patients from the WASID study suggested possible benefits of stent placement over medical treatment for severe (70%–99%) intracranial stenosis (stroke and death rate: 13% versus 16% at 6 months).12 However, a recent historical cohort study on severe (>50%) intracranial stenoses showed a similar combined ischemic event rate for the occurrence of TIA, stroke, and vascular death between patients receiving medical treatment and those receiving endovascular stent placement (24% versus 28.3%).13 More studies comparing long-term outcomes between medical treatment and endovascular stent placement for intracranial stenosis are, therefore, warranted, particularly in Asian populations. We conducted a longitudinal observation of 114 Taiwanese patients with angiographically proved severe (70%–99%) symptomatic intracranial stenosis, including 53 patients receiving endovascular stent placement and 61 matched patients receiving medical treatment, with immediate and long-term outcomes compared during a 3-year follow-up period.

Materials and Methods

Subject Enrollment

Patients with DSA-proved severe (70%–99%) symptomatic intracranial arterial stenosis at Taipei Veterans General Hospital between October 2002 and October 2009 were reviewed retrospectively. Specific causes other than atherosclerosis, such as Moyamoya syndrome, vasospasm, vasculitis, and compression stenosis secondary to tumor or infarction/hemorrhage, were excluded. The medical group received only medical treatment, and the stent-placement group received additional endovascular stent placement. The stent-placement group included all patients who had received intracranial stent placement between October 2002 and October 2009 at the center. Patients who underwent only endovascular angioplasties were excluded from this study. For a matched comparison, disabled patients with mRS scores of >3 in the medical group were excluded because the inclusion criterion for the stent-placement group was an mRS score of 1–3. The vascular risk factors/concomitant medical diseases, anatomic locations of stenosis, stenotic degree, and baseline mean mRS scores were all matched between the 2 groups to avoid selection bias (Table 1). The observation time was 3–36 months from the endovascular procedure in the stent-placement group (17 ± 11.0 months) or from the initial diagnosis in the medical group (17.2 ± 10.5 months). Patients with incomplete clinical data or unmatched demographic characteristics were excluded, as listed in the enrollment flow chart (On-line Fig 1).

View this table:
  • View inline
  • View popup
Table 1:

Baseline characteristics

Therapeutic Modalities

Endovascular angioplasty and stent placement were performed for patients with severe (70%–99%) symptomatic intracranial atherosclerosis despite antithrombotic and/or anticoagulant treatment. All patients in both stent-placement and medical groups were required to have preserved functional activities (mRS score, 1–3) and no contraindications for endovascular procedures (eg, contrast allergy, renal failure, coagulopathy, advanced malignancy). The decision was thoroughly discussed in a weekly conjoint conference of neurologists, neuroradiologists, and neurosurgeons. Following endovascular angioplasty and stent placement performed by qualified interventional neuroradiologists, patients were transferred to a stroke intensive care unit for strict blood pressure control to prevent hyperperfusion. Brain MR imaging, including DWI and ADC mapping, was performed on the day following intervention to exclude any asymptomatic complications. Double antiplatelet (aspirin and clopidogrel) therapy was given as standard treatment, if tolerated, from 1–3 days before to at least 3 months after the procedure.14 In-stent restenosis (>50%) was monitored by DSA or CT angiography at an interval of 3–6 months after stent placement, if possible. The patients in the medical group received single or double antiplatelet and/or anticoagulant treatment following the initial diagnosis. Most patients, although stent-eligible, refused the stent placement treatment (n = 55, 90.2%) because of the procedural risk and/or the expense. A few were stent amenable (n = 6, 9.8%) but had not been offered stent placement due to technical difficulties (3 with deep stenotic segments, 2 with tortuous carotid siphons, 1 with a concomitant aneurysm). Both groups were similarly managed and followed at our outpatient clinic on a monthly basis.

Data Collection

The demographic characteristics, vascular risk factors, comorbidities (hypertension, diabetes, hyperlipidemia, cigarette smoking, stroke/TIA, ischemic heart disease, peripheral arterial occlusive disease), presenting symptoms, initial diagnosis, clinical events, laboratory surveys, stent placement procedure, and clinical outcomes were reviewed by 2 neurologists through medical records, telephone calls, and outpatient visits. Clinical events were defined as stroke (ischemic or hemorrhagic), TIA, and vascular death other than stroke (including sudden death, death within 30 days after a myocardial infarction, pulmonary embolism, rupture of an aortic aneurysm, or acute ischemia of a limb or internal organ). Major events included disabling stroke and vascular death (mRS score, 4–6). Favorable functional outcome was defined as an mRS score of 0–3 in the absence of major events during the observation period. Identification of stroke or TIA was based on neurologic deficits and brain MR imaging, including DWI and ADC maps. The MR imaging and DSA of extra- and intracranial vessels were interpreted blindly by 2 neuroradiologists. The stenotic location and degree were estimated according to the method suggested by WASID.3,15 The available data regarding blood pressure, HbA1c, and total cholesterol throughout follow-up were evaluated.

Statistics

The statistical analyses of demographic characteristics between the stent-placement and the medical groups were conducted by using the χ2 test and/or the Fisher exact test and the Mann-Whitney U test and/or the Student t test. The Kaplan-Meier curve and the logrank test were used, respectively, to compare the cumulative event rates and functional outcomes of the 2 groups. Observation time was from the initial diagnosis to primary event occurrence, loss to follow-up, or the patient being event-free until 36 months. The multivariate regression analysis of possible factors related to periprocedural complications was conducted by using stepwise logistic regression including variables with P ≤ .15 on the univariate analysis. Statistical significance was defined as P < .05 in all tests. The analyses were performed by using the Statistical Package for the Social Sciences software, Version 17.0 (SPSS, Chicago, Illinois).

Results

Of the 114 patients enrolled, comprising 53 patients in the stent-placement group and 61 matched patients in the medical group, there were no significant differences between the 2 groups in terms of basic characteristics, including age, sex, vascular risk factors, presenting symptoms, follow-up time, baseline functional status, stenotic location, and degree of stenosis (Table 1). For all patients, the mean age was 66.5 ± 12 years old, and male sex was predominant (83%). The most common vascular risk factors were hypertension (∼80%), followed by diabetes mellitus (∼46%) and hyperlipidemia (∼34%). The presenting symptoms, including ischemic stroke and TIA, showed a similar incidence in the 2 groups (37% and 63%, respectively). Stenosis was slightly more common in the anterior circulation (59%) than in the posterior circulation (41%). The average degree of baseline stenosis was approximately 80% in both groups. Concomitant extracranial stenosis, rather than isolated intracranial stenosis, was more prevalent in the medical group than in the stent-placement group (54% versus 36%) but not significantly so (P = .09). The mean follow-up time was 17 months in both groups.

The total event rate was similar between the medical group (24.6%) and the stent-placement group (26.6%) during the observation period of 3 years, and the 1-year estimated event rates were 23% and 22%, respectively (On-line Table and Fig 1A). The major event rate was higher in the medical group (9.8%) than in the stent-placement group (3.2%, P = .31). Most important, the stent-placement group had a significantly more favorable functional outcome than the medical group (94.3% versus 78.7% with mRS scores of 0–3, P = .045). Both groups began with similar distributions of baseline mRS (1–3) but ended with a marked difference in functional outcomes. In particular, the stent-placement group had an increased proportion of asymptomatic patients (30.2% with mRS of 0) and a decreased proportion of patients with disability (5.7% with mRS scores of 4–6) compared with the medical group (Fig 2). Furthermore, the timing of clinical events was different between the 2 groups. The stent-placement group had 75% (9/12) of events clustered in the first week after the procedure as periprocedural events (incidence, 17.0%). Thereafter, there were only 1 ischemic stroke and 1 TIA during the 3-year follow-up.

Fig 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 1.

A, Kaplan-Meier curve of cumulative event-free probability. Note the stent-placement group drops 17% within the first week due to periprocedural complications and then slides modestly thereafter. In contrast, the medical group declines progressively with time. After 3 years, the event-free probabilities of the 2 groups fall similarly. B, Kaplan-Meier curve of cumulative favorable probability defined as mRS scores of 0–3. Note that the stent-placement group has a markedly better long-term functional outcome (P = .045).

Fig 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 2.

The distribution of baseline and final mRS scores of the medical and stent-placement groups

In contrast, the medical group had progressively increasing events with time after the initial diagnosis (Fig 1A) and a significant cumulative disabling outcome (Fig 1B), as illustrated by the Kaplan-Meier curves. Long-term events in the medical group included 11 ischemic strokes and 1 TIA: More than half were ipsilateral to the severely stenotic artery, suggesting poor collaterals despite medical treatment. In-stent restenosis was infrequently observed in the stent-placement group and included 1 patient with TIA at 5 months after stent placement with a balloon-mounted stent over the carotid siphon and another who was asymptomatic at 15.8 months with a self-expandable stent over the vertebral artery. The 1-year probability of in-stent restenosis was 4%. The medical group rarely had follow-up DSA, making stenotic progression difficult to estimate. Vascular risk factors, such as blood pressure, HbA1c, and total cholesterol, were similarly controlled between the 2 groups throughout the observation period, though patients in the stent-placement group tended to have a lower systolic blood pressure than those in the medical group (129.3 ± 14.7 versus 142.5 ± 24.4 mm Hg).

The technical success rate in the stent-placement group, defined as residual stenosis <50%, was 98.1% in a total of 71 stents at 56 stenotic arteries in 53 patients; there was 1 marginal (60%) residual stenosis. All periprocedural complications were observed within 3 days following intervention and were usually minor strokes (mRS, 1–3), except for 1 serious intracranial and subarachnoid hemorrhage from the carotid siphon (mRS 5, Table 2). Most stents were balloon-mounted (91.5%), and only 6 were self-expandable, because the latter type was undergoing an early trial for intracranial applications according to the Department of Health of Taiwan. The most common stenotic sites subjected to endovascular intervention were the intracranial carotid and vertebral arteries, whereas the most frequently complicated sites were the MCA and the BA, with total event rates of 42.9% for both (Fig 3). Perforator infarction with balloon-mounted stents placed at the perforator-rich MCA and BA was usually observed. The stent-placement sites were independent factors in predicting periprocedural ischemic stroke, whereas no other factors, including age, sex, stenotic degree, anterior or posterior circulation, and vascular risk factors, were significantly correlated with periprocedural complications on multivariate regression analysis.

View this table:
  • View inline
  • View popup
Table 2:

Periprocedural complications in the stenting group

Fig 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 3.

Total clinical events of different stenotic arteries subjected to stent placement. The ICA and VA were the 2 most common interventional sites. Note that the perforator-rich MCA and BA have the most clinical events.

Discussion

Whether endovascular stent placement is superior to medical treatment for intracranial stenosis has been fiercely debated.16–19 In this historical cohort study, 3-year outcomes were compared between endovascular stent placement and medical treatments in 114 Taiwanese patients with angiographically documented severe intracranial stenosis; there was no difference in total event rates between the 2 groups. Although the groups were similar in total event rates, the major event rate was lower in the stent-placement group (1, 3.2%) than in the medical group (5, 9.8%, P = .31). The events in the stent-placement group were mostly minor strokes in the first periprocedural week but markedly decreased thereafter compared with the medical group. Most major events in the medical group were large cerebral infarctions within the territory of the stenotic artery. Notably, the stent-placement group had a significantly favorable long-term outcome, and the benefit might arise from augmented reperfusion and collaterals, improved cerebrovascular autoregulation, motivated compliance for risk-factor control, low in-stent restenosis, and fewer major events.

The present results are compatible with a recent historical cohort study that showed a similar combined ischemic event rate and functional outcome between medical- and stent-treated patients with intracranial stenosis, though stenotic degree >50% was not further classified.13 There was another report in abstract form from the NIH Wingspan Multicenter Stent Placement Registry suggesting a possible benefit of stent placement in cases of 70%–99% intracranial stenosis during a 6-month observation period in comparison with matched medical controls from the WASID trial.12,20 In the present study, a long-term functional benefit of stent placement was seen in 70%–99% symptomatic intracranial stenoses in terms of no major stroke and mRS scores between 0 and 3. However, the medical group had considerably more concomitant extracranial stenoses, which might exert influence on outcome measures. Moreover, limited information concerning long-term risk-factor management and angiographic stenotic progression also restricted our interpretations. We await the ongoing Stent Placement and Aggressive Medical Management for Preventing Stroke in Intracranial Stenosis trial for 70%–99% stenosis (http://clinicaltrials.gov) to validate the long-term outcomes of the 2 therapeutic modalities.

To reduce subsequent stroke associated with intracranial stenosis, the timely treatment of risk factors is warranted.4,21–23 Antithromboembolic agents act in concert with aggressive management of risk factors for plaque stabilization and regression.21 In our medical group, the incidence of ischemic events in the first year was 85% (11 of 13), similar to the rate (78%) observed in the WASID study.3 This suggests little benefit of delayed stent placement after a year. Furthermore, 69% (9 of 13) of the ischemic events in the medical group occurred in the territory of the stenotic artery, also similar to the rate of 73% in the WASID study.24 Of these, half (56%) were in the MCA territory.

The technical success rate of stent placement was 98.1% in our study; with failure in only 1 patient who had a marginal 60% residual stenosis at a tortuous carotid siphon. The periprocedural complication rate within the first week was high (17.0%), though most were minor strokes (mRS 0–3, 88.9%). Previously reported periprocedural complication rates varied from 4.4% to 50%.7,8 Most such studies did not have poststenting brain MR imaging, as in the present study; therefore, the rate of subclinical strokes could have been underestimated. New ischemic foci after carotid stent placement were not uncommon (20%–50%) on DWI/ADC imaging, and most were silent ischemic strokes (∼38%).25 The most common periprocedural complications in the present study were perforator infarctions (4/6 ischemic events) that were related to balloon-mounted stents over the perforator-rich zones of the MCA and BA, similar to an earlier report (5 of 6 ischemic events in a total of 169 patients).26

Leung et al27 suggested using self-expandable stents at the perforator-rich MCA and reported no perforator infarction in 24 cases. We used 6 self-expandable stents, and none had periprocedural events, though 1 asymptomatic in-stent restenosis was found a year after stent placement at the VA. In a meta-analysis, self-expandable stents accounted for a higher restenotic rate (17.4%) than balloon-mounted stents (13.8%) during follow-up for 5–8 months.7 The self-expandable Wingspan stent system (Boston Scientific, Natick, Massachusetts) for intracranial stenosis accounted for 25%–30% of in-stent restenosis at 6 months' follow-up.28,29 In our study, low in-stent restenosis was observed (2/20, 10%) on angiographic follow-up for at least 6 months, probably because balloon-mounted stents were predominantly used (>90%). Strategically chosen stent types for different sites of intracranial stenosis should optimize therapeutic efficacy.

Conclusions

The total event rates between the stent-placement and the medical groups were similar for severe intracranial stenosis during a 3-year follow-up. However, the long-term functional outcomes were better in the stent-placement group. The favorable functional outcome resulted partially from the occurrence of fewer major events. The periprocedural complications of stent placement, particularly at the perforator-rich MCA and BA, may be partly prevented by selectively using self-expandable stents.

Acknowledgments

We thank Wen-Yung Sheng for assistance with statistics.

Footnotes

  • This work was supported by Veterans General Hospitals University System of Taiwan Joint Research Program (VGHUST99-P1–07), National Science Council (NSC-97–2314-B-480–002-MY3, 97–3111-B-010–004), and Taipei Veterans General Hospital (V98B2–008, V98E1–009, V99C1–069, V99E1–010) in Taiwan.

  • Indicates article with supplemental online table.

  • Indicates article with supplemental online figure.

Indicates open access to non-subscribers at www.ajnr.org

References

  1. 1.↵
    1. Suri MF,
    2. Johnston SC
    . Epidemiology of intracranial stenosis. J Neuroimaging 2009;19(suppl 1):11S–16S
    CrossRefPubMed
  2. 2.↵
    1. Kasner SE
    . Natural history of symptomatic intracranial arterial stenosis. J Neuroimaging 2009;19(suppl 1):20S–21S
    CrossRefPubMed
  3. 3.↵
    1. Chimowitz MI,
    2. Lynn MJ,
    3. Howlett-Smith H,
    4. et al
    . Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005;352:1305–16
    CrossRefPubMed
  4. 4.↵
    1. Kasner SE,
    2. Chimowitz MI,
    3. Lynn MJ,
    4. et al
    . Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis. Circulation 2006;113:555–63
    Abstract/FREE Full Text
  5. 5.↵
    1. Qureshi AI
    . Endovascular treatment of cerebrovascular diseases and intracranial neoplasms. Lancet 2004;363:804–13
    CrossRefPubMed
  6. 6.↵
    1. Derdeyn CP,
    2. Chimowitz MI
    . Angioplasty and stenting for atherosclerotic intracranial stenosis: rationale for a randomized clinical trial. Neuroimaging Clin N Am 2007;17:355–63, viii-ix
    CrossRefPubMed
  7. 7.↵
    1. Groschel K,
    2. Schnaudigel S,
    3. Pilgram SM,
    4. et al
    . A systematic review on outcome after stenting for intracranial atherosclerosis. Stroke 2009;40:e340–47
    Abstract/FREE Full Text
  8. 8.↵
    1. Cruz-Flores S,
    2. Diamond AL
    . Angioplasty for intracranial artery stenosis. Cochrane Database Syst Rev 2006;3:CD004133
    PubMed
  9. 9.↵
    1. Nahab F,
    2. Lynn MJ,
    3. Kasner SE,
    4. et al
    . Risk factors associated with major cerebrovascular complications after intracranial stenting. Neurology 2009;72:2014–19
    Abstract/FREE Full Text
  10. 10.↵
    1. Jiang WJ,
    2. Xu XT,
    3. Du B,
    4. et al
    . Comparison of elective stenting of severe vs moderate intracranial atherosclerotic stenosis. Neurology 2007;68:420–26
    Abstract/FREE Full Text
  11. 11.↵
    1. Kurre W,
    2. Berkefeld J,
    3. Brassel F,
    4. et al
    . In-hospital complication rates after stent treatment of 388 symptomatic intracranial stenoses: results from the INTRASTENT Multicentric Registry. Stroke 2010;41:494–98
    Abstract/FREE Full Text
  12. 12.↵
    1. Jarvis AL,
    2. Lynn MJ,
    3. Alexander MJ,
    4. et al
    . Outcome of patients with 50–99% intracranial stenosis and TIA or stroke on antithrombotic therapy treated medically vs stenting. In: Proceedings of the 60th Annual Meeting of the American Academy of Neurology. Chicago, Illinois; April 12–19, 2008
  13. 13.↵
    1. Samaniego EA,
    2. Hetzel S,
    3. Thirunarayanan S,
    4. et al
    . Outcome of symptomatic intracranial atherosclerotic disease. Stroke 2009;40:2983–87
    Abstract/FREE Full Text
  14. 14.↵
    1. Zaidat OO
    . Periprocedural management of patients with endovascular treatment of intracranial atherosclerotic disease. J Neuroimaging 2009;19(suppl 1):35S–38S
    CrossRefPubMed
  15. 15.↵
    1. Schumacher HC,
    2. Meyers PM,
    3. Higashida RT,
    4. et al
    . Reporting standards for angioplasty and stent-assisted angioplasty for intracranial atherosclerosis. Stroke 2009;40:e348–65
    CrossRef
  16. 16.↵
    1. Qureshi AI,
    2. Feldmann E,
    3. Gomez CR,
    4. et al
    . Consensus conference on intracranial atherosclerotic disease: rationale, methodology, and results. J Neuroimaging 2009;19(suppl 1):1S–10S
    CrossRef
  17. 17.↵
    1. Qureshi AI,
    2. Feldmann E,
    3. Gomez CR,
    4. et al
    . Intracranial atherosclerotic disease: an update. Ann Neurol 2009;66:730–38
    CrossRefPubMed
  18. 18.↵
    1. Higashida RT,
    2. Meyers PM,
    3. Connors JJ,
    4. et al
    . Intracranial angioplasty and stenting for cerebral atherosclerosis: a position statement of the American Society of Interventional and Therapeutic Neuroradiology, Society of Interventional Radiology, and the American Society of Neuroradiology. J Vasc Interv Radiol 2005;16:1281–85
    PubMed
  19. 19.↵
    1. Sacco RL,
    2. Adams R,
    3. Albers G,
    4. et al
    . Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke—co-sponsored by the Council on Cardiovascular Radiology and Intervention. The American Academy of Neurology affirms the value of this guideline. Circulation 2006;113:e409–49
  20. 20.↵
    1. Rasmussen PA
    . The evolution and role of endovascular therapy for the treatment of intracranial atherosclerotic disease. J Neuroimaging 2009;19(suppl 1):30S–34S
    CrossRefPubMed
  21. 21.↵
    1. Gomez CR,
    2. Qureshi AI
    . Medical treatment of patients with intracranial atherosclerotic disease. J Neuroimaging 2009;19(suppl 1):25S–29S
    CrossRefPubMed
  22. 22.↵
    1. Mazighi M,
    2. Tanasescu R,
    3. Ducrocq X,
    4. et al
    . Prospective study of symptomatic atherothrombotic intracranial stenoses: the GESICA study. Neurology 2006;66:1187–91
    Abstract/FREE Full Text
  23. 23.↵
    1. Wong KS,
    2. Chen C,
    3. Ng PW,
    4. et al
    . Low-molecular-weight heparin compared with aspirin for the treatment of acute ischaemic stroke in Asian patients with large artery occlusive disease: a randomised study. Lancet Neurol 2007;6:407–13
    CrossRefPubMed
  24. 24.↵
    1. Famakin BM,
    2. Chimowitz MI,
    3. Lynn MJ,
    4. et al
    . Causes and severity of ischemic stroke in patients with symptomatic intracranial arterial stenosis. Stroke 2009;40:1999–2003
    Abstract/FREE Full Text
  25. 25.↵
    1. Bendszus M,
    2. Stoll G
    . Silent cerebral ischaemia: hidden fingerprints of invasive medical procedures. Lancet Neurol 2006; 5: 364–72
    CrossRefPubMed
  26. 26.↵
    1. Jiang WJ,
    2. Srivastava T,
    3. Gao F,
    4. et al
    . Perforator stroke after elective stenting of symptomatic intracranial stenosis. Neurology 2006;66:1868–72
    Abstract/FREE Full Text
  27. 27.↵
    1. Leung TW,
    2. Yu SC,
    3. Lam WW,
    4. et al
    . Would self-expanding stent occlude middle cerebral artery perforators? Stroke 2009;40:1910–12
    Abstract/FREE Full Text
  28. 28.↵
    1. Levy EI,
    2. Turk AS,
    3. Albuquerque FC,
    4. et al
    . Wingspan in-stent restenosis and thrombosis: incidence, clinical presentation, and management. Neurosurgery 2007;61:644–50, discussion 650–51
    PubMed
  29. 29.↵
    1. Zaidat OO,
    2. Klucznik R,
    3. Alexander MJ,
    4. et al
    . The NIH registry on use of the Wingspan stent for symptomatic 70–99% intracranial arterial stenosis. Neurology 2008;70:1518–24
    Abstract/FREE Full Text
  • Received July 19, 2010.
  • Accepted after revision September 21, 2010.
  • Copyright © American Society of Neuroradiology
View Abstract
PreviousNext
Back to top

In this issue

American Journal of Neuroradiology: 32 (5)
American Journal of Neuroradiology
Vol. 32, Issue 5
1 May 2011
  • Table of Contents
  • Index by author
Advertisement
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on American Journal of Neuroradiology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Stenting versus Medical Treatment for Severe Symptomatic Intracranial Stenosis
(Your Name) has sent you a message from American Journal of Neuroradiology
(Your Name) thought you would like to see the American Journal of Neuroradiology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Cite this article
C.-W. Tang, F.-C. Chang, C.-M. Chern, Y.-C. Lee, H.-H. Hu, I.-H. Lee
Stenting versus Medical Treatment for Severe Symptomatic Intracranial Stenosis
American Journal of Neuroradiology May 2011, 32 (5) 911-916; DOI: 10.3174/ajnr.A2409

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
0 Responses
Respond to this article
Share
Bookmark this article
Stenting versus Medical Treatment for Severe Symptomatic Intracranial Stenosis
C.-W. Tang, F.-C. Chang, C.-M. Chern, Y.-C. Lee, H.-H. Hu, I.-H. Lee
American Journal of Neuroradiology May 2011, 32 (5) 911-916; DOI: 10.3174/ajnr.A2409
del.icio.us logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Purchase

Jump to section

  • Article
    • Abstract
    • Abbreviations
    • Materials and Methods
    • Results
    • Discussion
    • Conclusions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • Responses
  • References
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • Tmax >4 s volume predicts stroke recurrence in symptomatic intracranial atherosclerotic stenosis with optimal medical treatment
  • Incidence and Risk Factors of In-Stent Restenosis for Symptomatic Intracranial Atherosclerotic Stenosis: A Systematic Review and Meta-Analysis
  • Wingspan experience in the treatment of symptomatic intracranial atherosclerotic disease after antithrombotic failure
  • Standard of practice: endovascular treatment of intracranial atherosclerosis
  • Crossref (17)
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Effect of Stenting Plus Medical Therapy vs Medical Therapy Alone on Risk of Stroke and Death in Patients With Symptomatic Intracranial Stenosis
    Peng Gao, Tao Wang, Daming Wang, David S. Liebeskind, Huaizhang Shi, Tianxiao Li, Zhenwei Zhao, Yiling Cai, Wei Wu, Weiwen He, Jia Yu, Bingjie Zheng, Haibo Wang, Yangfeng Wu, Adam A. Dmytriw, Timo Krings, Colin P. Derdeyn, Liqun Jiao, Liqun Jiao, Daming Wang, Timo Krings, David S Libeskind, Huaizhang Shi, Tianxiao Li, Zhenwei Zhao, Wei Wu, Yiling Cai, Weiwen He, Shengping Huang, Long Yin, Yuxiang Gu, Hongqi Zhang, Feng Ling, Louis R. Caplan, Osama Zaidat, Simon Chun Ho YU, Qinjian Sun, Jie Lu, Yuhai Bao, Kun Yang, Haiqing Song, Wenhuo Chen, Haitao Chi, Shouchun Wang, Jin Zhang, Fei Chen, Shenmao Li, Xiaobo Zhang, Hong Sui, Weiwu Hu, Long Li, Yao Feng, Peng Gao, Tao Wang, Haibo Wang, Yidan Zhu, Bingjie Zheng, Peng Qi, Kunpeng Chen, Yingkun He, Jia Yu, Weigang Gong, Juan Du, Yongqiang Cui, Yachong Chen
    JAMA 2022 328 6
  • Incidence and Risk Factors of In-Stent Restenosis for Symptomatic Intracranial Atherosclerotic Stenosis: A Systematic Review and Meta-Analysis
    G. Peng, Y. Zhang, Z. Miao
    American Journal of Neuroradiology 2020 41 8
  • Comparison of high-resolution MRI with CT angiography and digital subtraction angiography for the evaluation of middle cerebral artery atherosclerotic steno-occlusive disease
    Qi Liu, Jun Huang, Andrew J. Degnan, Shiyue Chen, Jonathan H. Gillard, Zhongzhao Teng, Jianping Lu
    The International Journal of Cardiovascular Imaging 2013 29 7
  • Standard of practice: endovascular treatment of intracranial atherosclerosis: Table 1
    M Shazam Hussain, Justin F Fraser, Todd Abruzzo, Kristine A Blackham, Ketan R Bulsara, Colin P Derdeyn, Chirag D Gandhi, Joshua A Hirsch, Daniel P Hsu, Mahesh V Jayaraman, Philip M Meyers, Sandra Narayanan, Charles J Prestigiacomo, Peter A Rasmussen
    Journal of NeuroInterventional Surgery 2012 4 6
  • Wingspan experience in the treatment of symptomatic intracranial atherosclerotic disease after antithrombotic failure
    Edgar A Samaniego, Francesca Tari-Capone, Italo Linfante, Christine F Silva, Gabriela Spilberg, Matthew Gounis, Ajay K Wakhloo, Guilherme Dabus
    Journal of NeuroInterventional Surgery 2013 5 4
  • Comparison of NASCET and WASID criteria for the measurement of intracranial stenosis using digital subtraction and computed tomography angiography of the middle cerebral artery
    Jun Huang, Andrew J. Degnan, Qi Liu, Zhongzhao Teng, Chen Shi Yue, Jonathan H. Gillard, Jian Ping Lu
    Journal of Neuroradiology 2012 39 5
  • Reproducibility of Middle Cerebral Artery Stenosis Measurements by DSA: Comparison of the NASCET and WASID Methods
    Luguang Chen, Qian Zhan, Chao Ma, Qi Liu, Xuefeng Zhang, Xia Tian, Yuanliang Jiang, Yinmei Dong, Shiyue Chen, Jianping Lu, Rex Eugene Jung
    PLOS ONE 2015 10 6
  • Intracranial atheromatous disease treatment with the Wingspan stent system: Evaluation of clinical, procedural outcome and restenosis rate in a single-center series of 21 consecutive patients with acute and mid-term results
    Roberto Gandini, Antonio Chiaravalloti, Enrico Pampana, Francesco Massari, Daniele Morosetti, Sergio Spano, Giorgio Loreni, Giovanni Simonetti
    Clinical Neurology and Neurosurgery 2013 115 6
  • Endovascular Management of Intracranial Atherosclerosis
    Mohamed S. Teleb, Kaiz Asif, Alicia C. Castonguay, Osama O. Zaidat
    Neurosurgery Clinics of North America 2014 25 3
  • Seven years’ follow-up of comparative study between stenting and medication for treatment of symptomatic vertebrobasilar artery stenosis
    Jun Wang, Changyang Zhong, Yan Zhang, Yingnan Wei, Huili Liu, Chunli Wu, Yongxing Yan
    Interventional Neuroradiology 2018 24 1

More in this TOC Section

  • Optimizing Voxel Size in 3D Rotational Angiography
  • Neuroform Atlas Stent for Intracranial Aneurysms
  • Neurologic Complication in Transradial Angiography
Show more NEUROINTERVENTION

Similar Articles

Advertisement

Indexed Content

  • Current Issue
  • Accepted Manuscripts
  • Article Preview
  • Past Issues
  • Editorials
  • Editor's Choice
  • Fellows' Journal Club
  • Letters to the Editor
  • Video Articles

Cases

  • Case Collection
  • Archive - Case of the Week
  • Archive - Case of the Month
  • Archive - Classic Case

More from AJNR

  • Trainee Corner
  • Imaging Protocols
  • MRI Safety Corner

Multimedia

  • AJNR Podcasts
  • AJNR Scantastics

Resources

  • Turnaround Time
  • Submit a Manuscript
  • Submit a Video Article
  • Submit an eLetter to the Editor/Response
  • Manuscript Submission Guidelines
  • Statistical Tips
  • Fast Publishing of Accepted Manuscripts
  • Graphical Abstract Preparation
  • Imaging Protocol Submission
  • Evidence-Based Medicine Level Guide
  • Publishing Checklists
  • Author Policies
  • Become a Reviewer/Academy of Reviewers
  • News and Updates

About Us

  • About AJNR
  • Editorial Board
  • Editorial Board Alumni
  • Alerts
  • Permissions
  • Not an AJNR Subscriber? Join Now
  • Advertise with Us
  • Librarian Resources
  • Feedback
  • Terms and Conditions
  • AJNR Editorial Board Alumni

American Society of Neuroradiology

  • Not an ASNR Member? Join Now

© 2025 by the American Society of Neuroradiology All rights, including for text and data mining, AI training, and similar technologies, are reserved.
Print ISSN: 0195-6108 Online ISSN: 1936-959X

Powered by HighWire